ImmuneRegen BioSciences(R) Summarizes Previous 9 Months of Advances as Homspera(R) Development Continues
2009年12月24日 - 10:00PM
Marketwired
ImmuneRegen BioSciences Inc.®, a wholly owned subsidiary of IR
Biosciences Holdings Inc. (OTCBB: IRBS), ends 2009 with a
significantly deeper understanding of the mechanisms underlying the
demonstrated immunostimulatory activity of its development
candidate Homspera®, and additional partners and advisory members
who strengthen the Company's efforts to bring Homspera into human
testing.
Relationships forged over the past 3 calendar quarters have
included those with investigators at the University of Rochester
and the University of Pittsburgh, and the Company has entered into
a joint licensing agreement with the latter in the area of cancer
vaccine adjuvants. Both investigators have subsequently joined the
Company's Advisory Board and continue to support the Company's
research and grant submission activities.
With the support of those investigators as well as others,
multiple grant submissions have been made to NIH and BARDA
(Biomedical Advanced Research and Development Authority) , as well
as through the Armed Forces Institute of Pathology and Walter Reed
Army Medical Center through their Combat Wound Initiative Program.
NIH-funded studies in areas related to Idiopathic Pulmonary
Fibrosis, where the Company has filed its first IND
(Investigational New Drug application) with the U.S. Food and Drug
Administration (FDA), are being pursued at the University of
Rochester. Also, additional studies in Avian Influenza (H5N1) as
well as the currently pandemic Swine-originated Influenza A virus
(H1N1) have shown Homspera's efficacy in animal models in reducing
the impact of infection with these potentially debilitating
viruses.
Successful research studies have garnered the interest of
potential partners, among them the world-renowned peptide
manufacturer Bachem Inc., at which Homspera is being manufactured
in compliance with current Good Manufacturing Practice (cGMP)
standards. This material will be used in the necessary safety
studies that will be submitted to FDA to support advancement of
Homspera into initial human testing, which is planned to begin in
late 2010.
"We are quite pleased with the company's progress over the past
12 months. Our team has worked extremely diligently to advance our
work with Homspera with the hope this translates to great value for
our shareholders," said ImmuneRegen CEO Michael Wilhelm.
Recent press releases:
ImmuneRegen BioSciences'® Reports Efficacy of a New Adjuvant of
a Preventive Cancer Vaccine
Dec 21, 2009 08:00 ET
ImmuneRegen BioSciences'® Drug Candidate Homspera Confirms
Efficacy as Cancer Vaccine Adjuvant
Dec 14, 2009 08:00 ET
ImmuneRegen BioSciences® Reports Positive Results of Homspera®
in Treating Highly Pathogenic Influenza
Nov 10, 2009 08:00 ET
ImmuneRegen BioSciences® to Further Homspera® Research in Study
Funded by U.S. Government
Oct 22, 2009 08:00 ET
ImmuneRegen BioSciences® Initiates Homspera® Studies Against
Global Influenza Threat
Oct 12, 2009 08:00 ET
ImmuneRegen BioSciences® Announces Strategic Partnership With
Azopharma Product Development Group, Inc.
Sep 23, 2009 08:00 ET
ImmuneRegen BioSciences® Announces Partnership With Bachem,
Inc., for Manufacturing of Homspera®
Sep 22, 2009 08:00 ET
ImmuneRegen BioSciences® Partners With University of Rochester
in BARDA Funding Bid
Sep 09, 2009 08:00 ET
ImmuneRegen BioSciences® Announces Collaboration With Archimedes
Development Limited
Aug 26, 2009 08:00 ET
ImmuneRegen BioSciences Announces IND Submission for Homspera®
for the Treatment of Idiopathic Pulmonary Fibrosis
May 28, 2009 08:00 ET
ImmuneRegen BioSciences® Enters Into a Sponsored Research
Agreement With the University of Pittsburgh
May 14, 2009 08:00 ET
ImmuneRegen® Licenses Intellectual Property From University of
Pittsburgh to Further Develop Proprietary Compound
Apr 30, 2009 08:00 ET
ImmuneRegen BioSciences® Adds Renowned Scientists to Advisory
Board
Apr 14, 2009 08:00 ET
ImmuneRegen® BioSciences Partners With University of Rochester
Scientist to Explore Homspera® Activity Against Pulmonary
Fibrosis
Apr 07, 2009 08:00 ET
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR
BioSciences Holdings, Inc. (OTCBB: IRBS), is a development-stage
biotechnology company focused on the research, development and
licensing of Homspera®. Homspera is an adult stem cell active
compound that in study results has been shown to regenerate and
strengthen the immune system and enhance wound healing. Homspera is
being developed for potential use against infectious diseases as a
stand-alone or combination therapy and as a vaccine adjuvant. To
advance its mission, the Scottsdale, Arizona based company has
forged numerous study partnerships with industry and academic
leaders, including Celgene Cellular Therapeutics, HemoGenix,
Lovelace Respiratory Research Institute and Virion Systems. For
more information, please visit www.immuneregen.com.
Statements about ImmuneRegen's future expectations, including
statements about the potential use and scientific results for
ImmuneRegen's drug candidates, science and technology, and all
other statements in this press release other than historical facts,
are "forward-looking statements" within the meaning of Section 27A
of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934, and as that term is defined in the Private
Securities Litigation Reform Act of 1995. ImmuneRegen intends that
such forward-looking statements be subject to the safe harbors
created thereby. These future events may not occur as and when
expected, if at all, and, together with ImmuneRegen's business, are
subject to various risks and uncertainties. ImmuneRegen's actual
results could differ materially from expected results as a result
of a number of factors, including the uncertainties inherent in
research and development collaborations, pre-clinical and clinical
trials and product development programs (including, but not limited
to the fact that future results or research and development efforts
may prove less encouraging than current results or cause side
effects not observed in current pre-clinical trials), the
evaluation of potential opportunities, the level of corporate
expenditures and monies available for further studies, capital
market conditions, and others set forth in ImmuneRegen's periodic
report on Form 10-KSB for the year ended December 31, 2008 as filed
with the Securities and Exchange Commission. There are no
guarantees that any of ImmuneRegen's proposed products will prove
to be commercially successful. ImmuneRegen undertakes no duty to
update forward-looking statements.
Contact: Michael K. Wilhelm OR John Fermanis ImmuneRegen
BioSciences Inc. Phone: 480-922-3926 Email: Email Contact Email:
Email Contact
IR BioSciences (CE) (USOTC:IRBS)
過去 株価チャート
から 5 2024 まで 6 2024
IR BioSciences (CE) (USOTC:IRBS)
過去 株価チャート
から 6 2023 まで 6 2024